XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 99

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include PIKOOL. The owner is based in XIAMEN.

ROOM 1304-1, NO. 1110 JIMEI NORTH AVENUE, SOFTWARE

PARK PHASE III, TORCH HIGH TECH ZONE

XIAMEN , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

PIKOOL
PIKOOL
Registered 2024

Trademark Classifications

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD have?

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD file in?

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD's most well-known trademarks?

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as PIKOOL. These are among 1 currently registered trademark in the portfolio.

What is XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD's trademark registration success rate?

XIAMEN OULEDA NETWORK TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.